CellCentric

About CellCentric

CellCentric is a clinical-stage biopharmaceutical company focused on the development of a first-in-class oral p300/CBP inhibitor to treat multiple myeloma and other cancer types. The company is advancing inobrodib as a potential therapy for multiple myeloma and various hematological malignancies, aiming to bring effective cancer treatments to patients. Its work encompasses oncology drug development with a focus on targeted cancer therapies and translational science. Headquartered in the United Kingdom, CellCentric emphasizes science-driven, patient-focused development.